IL1B and breast cancer: NLRP3 also leads to a reduction in the antitumor immunity of T and NK cells, thus creating an inflammatory microenvironment supporting BC progression and metastasis by activating inflammatory signaling pathways, such as the NF-κB/STAT 1/3, and IL-1β/IL-1RI/β-catenin pathways (43, 75).